Yissum Research Development Company of the Hebrew University

From Wikipedia, the free encyclopedia

Yissum Research Development Company is the technology transfer company of the Hebrew University of Jerusalem.[1] Founded in 1964, it is the third tech transfer company in the world to be created, and seeks to convert research into commercial solutions.

Yissum has founded more than 170 start-up companies, over 100 of which are still active in 2020, registered over 10,750+ patents globally, and licensed over 1050+ technologies. Yissum's business partners include Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis, GRAIL, and many more.

Yissum has signed collaboration agreements with Cornell, UCBerkeley, Caltech, Carnegie Mellon University, Children's Medical Center, Columbia University, Harvard University, Johns Hopkins University, MIT, Mayo Clinic, Michigan State University, NYU, Northwestern University, Rockefeller University, Stanford University among other renowned educational institutions.

History[]

Yissum was founded in 1964 to protect and market the Hebrew University's intellectual property. Since its inception, Yissum has founded more than 170 start-up companies, over 100 of which are still active in 2020, registered over 10,750+ patents globally, and licensed over 1050+ technologies. Yissum's business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis, Teva GRAIL, and many more.

Yissum has signed collaboration agreements with Cornell, UCBerkeley, Caltech, Carnegie Mellon University, Children's Medical Center, Columbia University, Harvard University, Johns Hopkins University, MIT, Mayo Clinic, Michigan State University, NYU, Northwestern University, Rockefeller University, Stanford University among other renowned educational institutions.

In Israel, technology transfer entities are organized as companies, unlike the United States. In the United States technology transfer operations only began after the Bayh–Dole Act in 1982. Yissum is a for-profit company which is fully owned by the Hebrew University which is a not-for-profit entity. This makes Yissum a non-typical entity.

Yissum founded Integra Holdings in 2012.

In 2014, QLight Nanotech, a subsidiary of Yissum partly owned by Merck, opened an R&D facility in Jerusalem for developing advanced LED lighting and displaypanels.[2]

Yissum founded Agrinnovation in 2015.

Start-up companies[]

  • QLight Nanotech - A subsidiary of Yissum, is a start up partly owned by Merck KGaA. In 2013, QLight opened a new facility in Jerusalem.[3]
  • MobilEye[4]
  • BriefCam (Video Synopsis)[5]
  • HumanEyes
  • OrCam[6]
  • Ex Libris Group[7]

Active Start-Ups

BioCancell Ltd-Anchiano Therapeutics
Biosensor Applications Sweden
Futuragene (Former CBD)
Collplant Ltd
En-Gibton Ltd
Galinova - Novagali
HumanEyes Technologies Ltd
Intec Pharmaceuticals
MobilEye VISION TECHNOLOGIES LTD
Nanoptics Ltd
PLR (Protein Laboratories Rehovot)
Ravgalai Ltd (Rav-Galai)
Syndromex Ltd
Tiltan Pharma
Treatec 21 INDUSTRIES LTD (TreaTec21 Ltd)
Aferrix Ltd.
Bio Park
Tolarex/Enlivex
H2Q Water Industries Ltd
BriefCam Ltd.
Qlight Ltd.
CoolCite
HIL Applied Medical Ltd.
MacroBea
LipoMedix
Plant Array Ltd
LipoCure (former IDD)
Morflora LLC / Morflora Israel
Steam Coffee Culture LTD
Immune Pharmaceuticals Ltd.
Nanosys
Integra Holdings Ltd
Lyotropic Delivery Systems Ltd. (LDS)
Avraham Pharmaceuticals Ltd.
Paulee Cleantec
Melodea Ltd
Raziel Therapeutics Ltd.
InnerEye Ltd.
Ayana Pharma
OrCam Ltd.
I-Class (Previously Sefereshet Ltd.)
Valentis Nanotech Ltd.
Pepticom
Bactusense Ltd
Lipogreen
Seevix Material Sciences
HepaRx Ltd. (Hepy)
OphRx Ltd
Neteera Technologies
Clairion (MercuRemoval Ltd)
NanoAF
GuideIn Medical Ltd.
Voyager Medical Ltd.
BioNanoSim (BNS) Ltd.
Agrinnovation (Yissum) G.P. Ltd.
Ex Libris Ltd
AquiNovo LTD.
Kalytera Therapeutics
NrgStorEdge
NewStem Ltd
SpliSense
GemmaCert Ltd - Sensory detection of active ingredient, composition and dosage levels in cannabis plants (former Cannabi-Tech Ltd)
Tissue Dynamics
ChickP
Tefuture LTD
Nectin Therpeutics LTD.
APIX Nutrition Ltd.
Smart Resilin Ltd.
Betalin Therapeutics Ltd.
Prorogo LTD
Compira Labs
Amenity Analytics
DAGlabs (DAG Labs)
QED-it Systems Ltd.
Biobetter Ltd
NeoProl Ltd.
Trieye Ltd
Zion Pharmaceutical Ltd
BioBlast Pharma Ltd.
Future Meat Technologies LTD.
CardioVia Ltd
Better Juice Ltd
SolCold Ltd.
Trendit
My Or
Kiralis
QuantLR
SkinApp
SavorEat
MEDPNC
Quanabis
Celluflux Ltd
3Biotix AEON Bio Pharma
R&L Renew Senses
HighRAD
Pilpel Seeds Ltd.
REMODELESS CV LTD
BacoCure
Cognifiber
Amendis LTD
Catalife
VitaLunga
Sufresca

Products brought to market by Yissum[]

  • Exelon - A cholinesterase inhibitor, a type of medicine prescribed for people in the early or middle stages of Alzheimer's disease. Invented by Marta Weinstock-Rosin.
  • Doxil - additional information can be found also at Doxorubicin - For the treatment of patients with ovarian cancer. Invented by Yechezkal Barenholz and Alberto Gabizon.
  • PerioChip - For reduction of pocket depth in patients with chronic periodontitis. Invented by Michael Friedman, Michael Sela and Doron Steinberg
  • Cherry tomatoes and long shelf life tomatoes - Invented by Haim Rabinowitch and Nachum Kedar.
  • Hybrid peppers - Invented by Yonatan Elkind.
  • LO2 Eye Drops - Invented by Shabtay Dikstein
  • Cationorm - For relief to patients suffering from dry eye symptoms. Invented by Simon Benita.
  • UV-Pearl Technology - Invented by David Avnir

See also[]

References[]

  1. ^ Biojerusalem Database: Yissum Research Development Company
  2. ^ Merck-backed QLight opens new Jerusalem nanotech site
  3. ^ Merck-backed QLight opens new Jerusalem nanotech site
  4. ^ "Mobileye, a Maker of Automated Driving Systems, Raises $400 Million". New York Times. July 7, 2013.
  5. ^ Israel Hi-Tech Firm Helped Capture Boston Bombers
  6. ^ OrCam's $2,500 augmented reality glasses speak words aloud, help the visually impaired 'see'
  7. ^ Instant access, distant library, Helena Flusfeder, Times Higher Education; 13 November 1995
Retrieved from ""